Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.

@article{Mease2014BrodalumabAA,
  title={Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.},
  author={Philip J. Mease and Mark C. Genovese and Maria Greenwald and Christopher T. Ritchlin and Andr{\'e} D Beaulieu and Atul A Deodhar and Richard A. Newmark and Jing Yuan Feng and Ngozi Erondu and Ajay Nirula},
  journal={The New England journal of medicine},
  year={2014},
  volume={370 24},
  pages={
          2295-306
        }
}
BACKGROUND We assessed the efficacy and safety of brodalumab, a human monoclonal antibody against interleukin-17 receptor A (IL17RA), in a phase 2, randomized, double-blind, placebo-controlled study involving patients with psoriatic arthritis. METHODS We randomly assigned patients with active psoriatic arthritis to receive brodalumab (140 or 280 mg subcutaneously) or placebo on day 1 and at weeks 1, 2, 4, 6, 8, and 10. At week 12, patients who had not discontinued their participation in the… 

Tables from this paper

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.

Secuk inumab was more effective than placebo in patients with psoriatic arthritis, which validates interleukin-17A as a therapeutic target, and secondary end points, including the ACR50 response and joint structural damage, were significantly better in the secukinumab groups than in the placebo group.

Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials

Bdalumab was associated with rapid and significant improvements in signs and symptoms of PsA versus placebo and was well tolerated, with a safety profile consistent with other interleukin-17 inhibitors.

A Study to Evaluate the Safety, Tolerability, and Efficacy of Brodalumab in Subjects with Rheumatoid Arthritis and an Inadequate Response to Methotrexate

This study failed to find evidence of meaningful clinical efficacy with brodalumab treatment in subjects with RA who had an inadequate response to MTX, and preliminary results do not support further evaluation of brodalUMab as a treatment for RA.

Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review

This mechanism of blocking multiple IL-17 family cytokines differs from that of other available biologics which selectively target some parts of the Th-17 axis and may account for the effectiveness of brodalumab in patients poorly responsive to other biology, a feature which has also been shown where subgroup analysis has been undertaken in clinical trials.

Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials

Use of brodalumab revealed prompt clinical improvement and a favorable short-term safety profile in phase III trials, although further extension studies are needed to assess long- term safety.

Brodalumab-an IL-17RA monoclonal antibody for psoriasis and psoriatic arthritis

This review aims to summarize up-to-date pharmacological properties of brodalumab and the clinical efficacy and safety data presented in clinical trials and the focus of this review will be on psoriasis, psoriatic arthritis and rheumatoid arthritis.

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

In biologic-naive patients with active PsA, ixekizumab treatment resulted in improvements in disease activity and physical function, as well as in the inhibition of structural damage progression.

Brodalumab in the treatment of psoriatic arthritis – the latest reports

It is worth emphasizing that brodalumab was effective in phase II clinical trials in PsA patients, and it is worth getting acquainted with the latest phase III study, the results of which were published at the end of October 2020.

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)

Apremilast demonstrated clinically meaningful improvements in psoriatic arthritis and psoriasis at week 16; sustained improvements were seen with continued treatment through 52 weeks and generally well tolerated and demonstrated an acceptable safety profile.

Th17 Inhibitors in Active Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials

In patients with active PsA, biologics targeting the Th17 axis produce a clinically significant improvement in joint disease activity with acceptable safety and tolerability for short-term treatment compared to placebo.
...

References

SHOWING 1-10 OF 39 REFERENCES

Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.

Bdalumab significantly improved plaque psoriasis in this 12-week, phase 2 study and was superior to placebo in all comparisons.

A Study to Evaluate the Safety, Tolerability, and Efficacy of Brodalumab in Subjects with Rheumatoid Arthritis and an Inadequate Response to Methotrexate

This study failed to find evidence of meaningful clinical efficacy with brodalumab treatment in subjects with RA who had an inadequate response to MTX, and preliminary results do not support further evaluation of brodalUMab as a treatment for RA.

Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.

Use of a humanized anti-interleukin-17 monoclonal antibody, ixekizumab, improved the clinical symptoms of psoriasis and further studies are needed to establish its long-term safety and efficacy in patients with Psoriasis.

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

Although the primary endpoint was not met, clinical responses, acute-phase reactant and quality of life improvements were greater with secukinumab versus placebo, suggesting some clinical benefit.

Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.

Etanercept reduced joint symptoms, improved psoriatic lesions, inhibited radiographic progression, and was well tolerated in patients with PsA.

Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).

Therapy with infliximab at a dose of 5 mg/kg significantly improved the signs and symptoms of arthritis, psoriasis, dactylitis, and enthesitis in patients with active PsA that had been resistant to DMARD therapy.

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.

Infliximab 5 mg/kg through 24 weeks significantly improved active PsA, including dactylitis and enthesopathy, and associated psoriasis.

Effect of IL-17A blockade with secukinumab in autoimmune diseases

Findings on secukinumab provide evidence for the role of IL-17A in the pathophysiology of autoimmune disease and suggest the potential value of targeting this cytokine.

Anti-interleukin-17 treatment of psoriasis

The efficacy and safety results from the phase-3 trials with monoclonal antibodies targeting IL-17RA (brodalumab) and IL- 17A (ixekizumab and secukinumab), validateIL-17 as a highly effective therapeutic target for the treatment of plaque psoriasis.

IL-17 receptor and its functional significance in psoriatic arthritis

The hypothesis that IL-17RA blocking antibodies have the potential to be a therapeutic option for psoriatic arthritis is supported by results of this study.